Skip to main
OSTX

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies is globally recognized as a leader in developing innovative treatments for pediatric and young adult osteosarcoma, with its lead drug OST-HER2 demonstrating promising immune activation and potential for accelerated approval. The company's coordinated regulatory engagement and planned Phase 3 trial further de-risk its regulatory path, while the potential for a Priority Review Voucher presents a significant non-dilutive financing opportunity. However, potential risks such as clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share must be considered in the investment case.

Bears say

OS Therapies is a clinical-stage biopharmaceutical company with an innovative pipeline of immunotherapy and tunable drug conjugate treatments for solid cancers. However, the company faces significant risks in terms of clinical and regulatory hurdles, potential partnership and financial risks, as well as legal and intellectual property risks. Despite promising Phase 2b data and upcoming meetings with regulatory agencies, the focus should remain on whether biomarker data will be accepted for an accelerated approval pathway, creating uncertainty for investors in the near term.

OSTX has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 2 analysts, OSTX has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.